PTC-209 是一種特異性 BMI-1 抑制劑，HEK293T 細(xì)胞系中的 IC50 為 0.5 μM。

XMD8-92是一種 ERK5/BMK1 抑制劑，對(duì) BMK1、DCAMKL2、PLK4 和 TNK1 的 Kd 值分別為 80 nM、190 nM、600 nM 和 890 nM。

PRT4165是Bim1和Ring1A的抑制劑，能夠阻止PRC1（Polycomb-repressive complex 1）介導(dǎo)的H2A泛素化。

Unesbulin是一種口服活性且選擇性的 B 細(xì)胞特異性 Moloney 小鼠白血病病毒整合位點(diǎn) 1（BMI-1）抑制劑。PTC596 作用于腫瘤細(xì)胞和癌癥干細(xì)胞（CSCs）中表達(dá)的 BMI1，誘導(dǎo) BMI1 的過(guò)度磷酸化，從而導(dǎo)致其降解。PTC596 下調(diào) MCL-1，并在急性髓性白血病前體細(xì)胞中誘導(dǎo) p53 獨(dú)立的線粒體凋亡[1][2]

PTC-028 can decrease BMI-1 levels by posttranslational modification.

1,6,7-Trihydroxyxanthone, a natural product isolated and purified from the herbs of Garcinia cowa, has anti-cancer activity ,at least in part, through the activation of miR-218 and suppression of Bmi-1 expression and can suppress cell growth and induce apoptosis in liver cancer cells.

PTC-209 hydrobromide is a specific inhibitor for BMI-1 with IC50 of 0.5 μM in in both GEMS reporter and ELISA assays.